1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Demographic data for participant groups
Group No. of Patients (Sex) Age (y) Diagnosis (MS Subtype) Disease Duration (y) EDSS (Range) Healthy volunteers 7 (5 F) 44 ± 7 − − − All patients with MS 39 (21 F)a 49 ± 12 Relapsing-remitting (n = 14) 13 ± 11 1.0–7.0 Secondary-progressive (n = 10) Primary-progressive (n = 15) MS subgroup for quantitative analysis 10 (9 F) 47 ± 12 Relapsing-remitting (n = 4) 17 ± 14 1.0–6.5 Secondary-progressive (n = 5) Primary-progressive (n = 1)
↵a One of 40 patients recruited was dropped from the analysis when clinically diagnosed with neuromyelitis optica.